4.73
+5.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Precigen
From its filings with the US Securities and Exchange Commission
Precigen is based in Germantown, Maryland and is incorporated in Virginia. Its shares trade on Nasdaq under the ticker PGEN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $9.7m and a net loss of $250.6m. At that date it held total assets of $155.5m and shareholders' equity of $20.9m.
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including AdenoVerse immunotherapy, and UltraCAR-T, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Aug 2013
- Employees
- 160
- Website
- dna.com ↗
- Head office
- 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876
- Incorporated in
- VA
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Randal KirkExecutive Chairman of the Board, since 2008$600,000
- Dr. Helen SabzevariPresident, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc., since 2017$5.4m
- Mr. Harry ThomasianChief Financial Officer$1.4m
- Mr. Rutul ShahChief Operating Officer$1.4m
- Mr. Phil TennantChief Commercial Officer$518,337
- Mr. Donald LehrChief Legal Officer, Corporate Secretary$1.4m
- Mr. James TurleyLead Independent Director$313,000
- Ms. Nancy AgeeIndependent Director$385,075
- Mr. Cesar AlvarezIndependent Director$313,000
- Mr. Steven FrankIndependent Director$300,000
- Ms. Vinita GuptaIndependent Director$313,000
- Mr. Fred HassanIndependent Director$313,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 48
- Social
- 19
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Precigen Inc. has a strong reputation and a well-established presence in the biotechnology industry. The company possesses advanced technological capabilities and a diverse portfolio of innovative products and services. Precigen Inc. has a team of highly skilled professionals who contribute to its success. Moreover, the company has a robust financial position, providing stability and the ability to invest in research and development.
Weaknesses
- One of the weaknesses of Precigen Inc. is its dependency on few key customers. This creates a risk of revenue concentration and potential financial impact if any of these customers reduce or discontinue their business with the company. Additionally, Precigen Inc. may face challenges in scaling up its operations and managing growth, which can hinder its ability to effectively meet market demand.
Opportunities
- The biotechnology industry is constantly evolving, presenting numerous opportunities for Precigen Inc. to expand its product offerings and diversify its revenue streams. The increasing demand for advanced genetic engineering and gene editing technologies opens up new avenues for the company. Precigen Inc. can also benefit from strategic collaborations and partnerships to leverage complementary expertise and gain access to new markets.
Threats
- Precigen Inc. operates in a highly competitive industry, facing threats from both established players and emerging companies. Rapid technological advancements, regulatory changes, and intellectual property disputes pose risks to the company's market position and profitability. External factors, such as economic downturns or geopolitical uncertainties, can impact customer spending and overall demand for biotechnology products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.